Clinical Trials

25 results for Kidney/Renal Cancer


Combined Haploidentical Reduced Intensity Bone Marrow and Kidney Transplantation for Patients With Chronic Kidney Disease and Advanced Hematological Disorders

  • Condition: Chronic Kidney Disease, Acute Myeloid Leukemia (AML), Acute Lymphoblastic Leukemia (ALL), Chronic Myelogenous Leukemia (CML), Chronic Lymphocytic Leukemia (CLL), Non-Hodgkin's Lymphoma (NHL), Hodgkin Disease, Multiple Myeloma, Myelodysplastic Synd
  • Intervention: Procedure: Haploidentical Bone Marrow/Kidney
  • Study ID: NCT01758042
View Trial

An Open-label, Phase II, Registry Study of Lutetium-177 [DOTA0, Tyr3] Octreotate (Lu-DOTA-TATE) Treatment in Subjects With Somatostatin Receptor Positive Tumours

  • Condition: Carcinoma, Neuroendocrine
  • Intervention: Other: Lu-DOTA-TATE radiopharmaceutical
  • Study ID: NCT01876771
View Trial

Phase Ib Trial Of Pembrolizumab And Nintedanib

  • Condition: Patients With Any Advanced Solid Tumors.
  • Intervention: Drug: Nintedanib, Drug: Pembrolizumab
  • Study ID: NCT02856425
View Trial

FASTERCC: Folic Acid Supplement Versus Placebo for Treating Mucositis Adverse Events in Metastatic Renal Cell Carcinoma Patients Receiving Targeted Therapy. A Randomized, Double-blind Trial From the Danish Renal Cancer Group (DARENCA Study-4)

  • Condition: Mucositis
  • Study ID: NCT03581773
View Trial

REPLICA: Real Patient Life Treatment With Cabozantinib in Patients With Advanced or Metastatic RCC: A Descriptive and Prospective Non-Interventional Study

  • Condition: Advanced or Metastatic Renal Cell Carcinoma
  • Study ID: NCT04106349
View Trial

A Phase II Randomized Trial of Radium-223 Dichloride and Cabozantinib in Patients With Advanced Renal Cell Carcinoma With Bone Metastasis (RadiCal)

  • Condition: Advanced Renal Cell Carcinoma, Chromophobe Renal Cell Carcinoma, Clear Cell Renal Cell Carcinoma, Collecting Duct Carcinoma, Kidney Medullary Carcinoma, Metastatic Malignant Neoplasm in the Bone, Papillary Renal Cell Carcinoma, Stage IV Renal Cell
  • Study ID: NCT04071223
View Trial

A Phase I, Open-label, Multi-center Study of KFA115 as a Single Agent and in Combination With Tislelizumab in Patients With Select Advanced Cancers

  • Condition: Carcinoma, Non-Small-Cell Lung, Cutaneous Melanoma, Carcinoma, Renal Cell, Carcinoma, Ovarian Epithelial, Nasopharyngeal Carcinoma, Carcinoma, Thymic, Anal Cancer, Mesothelioma, Esophagogastric Cancer, High Microsatellite Instability Colorectal C
  • Study ID: NCT05544929
View Trial

Randomized Phase II Stereotactic Ablative Radiation Therapy (SABR) for Metastatic Unresected Renal Cell Carcinoma (RCC) Receiving Immunotherapy (SAMURAI)

  • Condition: Metastatic Renal Cell Carcinoma, Stage III Renal Cell Cancer AJCC v8, Stage IV Renal Cell Cancer AJCC v8, Unresectable Renal Cell Carcinoma
  • Study ID: NCT05327686
View Trial

Phase 2 Study of Combination Tivozanib and Nivolumab in Advanced Non-Clear Cell Renal Cell Carcinoma

  • Condition: Renal Cell Carcinoma
  • Study ID: NCT06053658
View Trial

An Open-label, Investigator-initiated, Single Arm, Exploratory Phase 2 Trial Evaluating the Feasibility and Efficiency of PET/CT Directed Free of Therapy Used for Metastatic and Advanced Renal Cell Carcinoma

  • Condition: Renal Cell Carcinoma (RCC), Metastatic Renal Cell Carcinoma (mRCC)
  • Study ID: NCT07175480
View Trial

Characterizing the Tumor-draining Lymph Nodes and Other Immune Sites in Renal Cell Carcinoma

  • Condition: Renal Cell Carcinoma (RCC)
  • Study ID: NCT07038733
View Trial

Cabozantinib and Nivolumab Among Older Patients With Renal-cell Carcinoma, a Prospective Cohort With Geriatric, Pharmacologic and Patient-reported-outcome Evaluation

  • Condition: Kidney Cancer, Renal Cell Cancer
  • Study ID: NCT06934057
View Trial

A Multicenter, Randomized, Double-Blind, Parallel-Controlled Phase I Clinical Study to Evaluate the Pharmacokinetic Profile, Efficacy, Safety and Immunogenicity of HLX17 vs. Keytruda® (US-sourced Keytruda®) in Multiple Resected Solid Tumors

  • Condition: Non-small Cell Lung Cancer, Melanoma, Renal Cell Carcinoma
  • Study ID: NCT07160335
View Trial

Patient-partnered Research: a Key to Investigating Fear of Cancer Recurrence in Patients With Surgically Treated Kidney Cancer (PP-RECURK)

  • Condition: Fear of Cancer Recurrence, Renal Cell Carcinoma (Kidney Cancer)
  • Study ID: NCT07234656
View Trial

Study on the Diagnostic Value of Novel PET Molecular Imaging for Renal Cell Carcinoma

  • Condition: Renal Cell Carcinoma
  • Study ID: NCT07301827
View Trial

A Phase 3, Randomized, Open-label Study of Belzutifan + Zanzalintinib Versus Cabozantinib in Participants With Advanced RCC Who Experienced Disease Recurrence During or After Prior Adjuvant Anti-PD-1/L1 Therapy (LITESPARK-033)

  • Condition: Renal Cell Carcinoma
  • Study ID: NCT07227402
View Trial

An Open, Multicenter Phase Ib/II Clinical Study of SHR-8068 in Combination With Adebrelimab and Other Anti-tumor Drugs for the Treatment of Advanced Renal Cell Carcinoma

  • Condition: Advanced Renal Cell Carcinoma
  • Study ID: NCT07239596
View Trial

A Phase 1/2a Study of the Safety, Tolerability, and Preliminary Clinical Activity of 177LuBetaBart, a 177Lu-Labeled Anti-B7-H3 Monoclonal Antibody, in Patients With Relapsed/Refractory, Locally Advanced Inoperable, or Metastatic Solid Tumors

  • Condition: Castration-Resistant Prostate Cancer (CRPC), Colorectal Cancer, NSCLC (Non-small Cell Lung Cancer), Ovarian Cancer, Cervical Cancer, Endometrial Cancer, TNBC, Triple Negative Breast Cancer, Small Cell Lung Cancer (SCLC ), Head &Amp; Neck Squamous
  • Study ID: NCT07189871
View Trial

The Impact of Cold Ischemia on Recovery From Ischemia After Robot-assisted Partial Nephrectomy: A Randomized Controlled Clinical Study

  • Condition: Renal Cell Carcinoma, Renal Function Abnormal
  • Study ID: NCT07326280
View Trial

ROSETTA RCC-208: A Phase 1/2 Open-label, Multi-center, Randomized Study of Pumitamig Alone or in Combination With Ipilimumab or Cabozantinib in Participants With Advanced Renal Cell Carcinoma (RCC)

  • Condition: Advanced Renal Cell Carcinoma (RCC)
  • Study ID: NCT07293351
View Trial

A Randomized Study of Nivolumab and Ipilimumab With and Without EXL01 in First-Line Treatment of Metastatic Renal Cell Carcinoma (mRCC)

  • Condition: Advanced Clear Cell Renal Cell Carcinoma, Advanced Sarcomatoid Renal Cell Carcinoma, Metastatic Clear Cell Renal Cell Carcinoma, Metastatic Sarcomatoid Renal Cell Carcinoma, Stage III Renal Cell Cancer AJCC v8, Stage IV Renal Cell Cancer AJCC v8
  • Study ID: NCT07128680
View Trial

AN INTERVENTIONAL PHASE 1B/2 STUDY TO EVALUATE THE SAFETY AND EFFICACY OF PF-08634404 MONOTHERAPY AND IN COMBINATION WITH OTHER ANTICANCER AGENTS IN ADULT PARTICIPANTS WITH LOCALLY ADVANCED OR METASTATIC RENAL CELL CARCINOMA

  • Condition: Carcinoma, Renal Cell, Advanced Renal Cell Carcinoma, Renal Cancer, Renal Neoplasm, Clear Cell Renal Cell Carcinoma, Metastatic Renal Cell Carcinoma, Clear-cell Metastatic Renal Cell Carcinoma, Carcinoma, Renal Cell Metastasis, Advanced or Metasta
  • Study ID: NCT07227415
View Trial

A Randomized Phase 2 Trial of Fianlimab and Cemiplimab +/- Ipilimumab or Ipilimumab Plus Nivolumab in First-line Advanced Renal Cell Carcinoma (RCC)

  • Condition: Advanced Renal Cell Carcinoma (aRCC), Metastatic Renal Cell Carcinoma ( mRCC), Clear Cell Renal Cell Carcinoma (ccRCC)
  • Study ID: NCT07188896
View Trial

Post-immunotherapy Nephrectomy for Metastatic Kidney Cancer After Complete or Major Response to Systemic Therapy

  • Condition: Kidney Cancer
  • Study ID: NCT06882486
View Trial

Targeted Decision Making In Renal Cell Carcinoma Relying on a Radiogenomics Translational Platform

  • Condition: Renal Tumors
  • Study ID: NCT06868927
View Trial